Clinical Trial Update: Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of Care

View source ↗

Summary

Expanded access program for GL-ONC1 in patients with advanced solid tumors and acute myeloid leukemia is no longer available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Solid Tumors

Drugs mentioned

• GL-ONC1

Snippet

Sponsor: Genelux Corporation | Conditions: Advanced Stage Cancer (Solid Tumor Disease for 4 Patients), Acute Myeloid Leukemia (6 Patients) | Status: NO_LONGER_AVAILABLE